Navigation Links
MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
Date:4/10/2008

er section 28, board 9) - Jon Cheesebrough, Tuesday,

April 15 from 1:00 - 5:00 p.m. in Exhibit Hall B-F.

-- IPI-504, a Selective Hsp90 Inhibitor is Biologically Active and

Tolerated in Combination with Trastuzumab in Preclinical Models of HER2

Positive Tumor Xenografts (Poster Session: Drug Discovery 2:

Combination Strategies I, abstract 4008, poster section 29, board 6)

- Ching Ching Leow, Ph.D., Tuesday, April 15 from 8:00 a.m. - 12:00

p.m. in Exhibit Hall B-F.

-- Bioavailability, Pharmacodynamic Activity, and Anti-Tumor Efficacy of

the CD19/CD3-Specific BiTE Antibody MEDI-538 (MT103) Delivered

Subcutaneously in Animal Models (Poster Session: Antibodies and

Immunotherapy, abstract 2131, poster section 23, board 6) - Kathy

Mulgrew, Monday, April 14 from 8:00 a.m. - 12:00 p.m. in Exhibit Hall

B-F.

-- Inhibition of Growth of Human Lymphoma Xenografts with a

Glycoengineered Antibody Specific for the B-Cell Antigen CD19 (Poster

Session: Antibodies and Immunotherapy, abstract 3980, poster section

28, board 8) - Beth K. Ward, Tuesday, April 15 from 8:00 a.m. - 12:00

p.m. in Exhibit Hall B-F.

-- The Characterization of a Potent, Fully Human MCP-1 Antibody In Vitro

and In Vivo (Poster Session: Antibodies, abstract 3986, poster section

28, board 14) - Z. Alexander Cao, Ph.D., Tuesday, April 15 from 8:00

a.m. - 12:00 p.m. in Exhibit Hall B-F.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on cardiovascular/gastrointestinal disease, neuroscience, oncology, infection, respiratory disease and inflammation. With approximately 3,000 employees worldwide and headquarters in Maryland, Me
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Seneca Valley High School Student Receives Science Award From MedImmune
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial ... The net income for the first quarter ended March ... of $14.1 million during the same period in 2010. Net ... related primarily to the $34.2 million in collaboration revenue recognized ...
... 2011 Silence Therapeutics plc (AIM: ... of patent 4,705,370, titled "Further Novel Forms of ...  The issued patent covers aspects of Silence,s platform ... 2,-O-Methyl structures known as AtuRNAi.  Silence,s AtuRNAi molecules ...
... May 2, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the quarter ended March 31, 2011 was $28.1 million ... The GAAP net loss for the quarter ended March ... $125.7 million, or $0.96 per share for the quarter ended March ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 2Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 3Dendreon Reports First Quarter 2011 Financial Results 2Dendreon Reports First Quarter 2011 Financial Results 3Dendreon Reports First Quarter 2011 Financial Results 4Dendreon Reports First Quarter 2011 Financial Results 5
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... 25, 2012  ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... its BluScience ( www.bluscience.com ) line ... McKesson to approximately 4,000 independent drugstores and pharmacies. ...
... five leading causes of death. And yet, despite ... treatment for most cancers. In addition, disappointing results ... the need for alternative methods. Mathematical ... of tumors in terms of differential equations and ...
... Research!America,s Board chair, former Congressman John Edward Porter (R-IL), ... in basic research. , "America,s leadership is at ... in discovery and development," said Porter. "We could ... Europe integrate science and technology into economic growth while ...
Cached Biology News:ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 2ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 3ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 4Aiding cancer therapy by mathematically modeling tumor-immune interactions 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 3State of the Union speech: Promising outlook for research and innovation 2
... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
... EIA Principle: Glutathion-S-transferases (GST) ... are involved in the detoxification processes. ... subgroups: Alpha, Mu, Pi, Teta and ... physiochemical, immunological, enzymatic and s Sample ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... RNA Aptamer Microarray contains greater than 1500 ...
Biology Products: